



**Fall 2021 - Virtual Symposium**  
*Can we target the MEF2-class IIa HDACs axis to sustain immunotherapy?*  
October 5<sup>th</sup> from 2.00 pm  
**The program**

**2.00: Claudio Brancolini**

Dep. of Medicine Università degli Studi di Udine (Italy)

- **Welcome and opening**

**2.10: Antonello Mai**

Dip. Chimica e Tecn. del Farmaco, Sapienza Università di Roma (Italy)

- **“Epigenetics: one score, several symphonies“**

2.35: Discussion

**2.45: Franz-Josef Meyer-Almes**

Dep. of Chemical Engineering and Biotechnology, University of Applied Sciences, Darmstadt (Germany)

- **“Novel HDAC-inhibitors with thiazolidinedione warheads“**

3.10: Discussion

**3.20: Maribel Parra**

Lymphocyte Development and Disease Lab Josep Carreras Leukaemia Research Institute, Barcelona, (Spain)

- **“Role of HDAC7 in normal and aberrant B cell lymphopoiesis “**

3.55: Discussion

**4.05: Wayne W. Hancock**

Dep. of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, (USA)

- **“Targeting the MEF2-class IIa HDACs axis for immunotherapy “**

4.30: Discussion

**4.40: Renato Ostuni**

Genomics of the Innate Immune System Unit, San Raffaele Telethon Institute for Gene Therapy Milano (Italy)

- **“A PGE 2-MEF2A axis enables context-dependent control of inflammatory gene expression“**

5.05 Discussion

**5.15: Final discussion**

